News | February 08, 2022
Merck KGaA restructures life science business to support long-term growth
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Acute therapies continue to report strong growth compared to chronic ones.
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Subscribe To Our Newsletter & Stay Updated
